secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211929
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Definium Therapeutics Q1 2026: cash $373.4M; three Phase 3 readouts for DT120 ODT expected in coming months
--------------------------------------------------------------------------------

- Cash and investments $373.4M as of March 31, 2026; expected to fund operations into 2028.
- R&D expenses $41.5M (up $18.1M YoY) driven by DT120 ODT program costs; G&A $17.7M (up $8.9M).
- Three Phase 3 topline data readouts for DT120 ODT anticipated: Emerge (MDD) late Q2 2026, Voyage (GAD) early Q3, Panorama (GAD) late Q3.
- DT120 ODT program expanded into PTSD; Phase 3 Haven study expected to initiate in 2027 with ~200 patients.
- Ascend (MDD) trial first patient dosing expected Q2 2026; enrollment complete in Emerge and Voyage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526211929/0001193125-26-211929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526211929/dftx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer